“Malaria Vaccine Offers Hope to Africa”

Return to Vaccination News Home Page __» Right-click to "open in new window"

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

The Malaria Vaccine Initiative is to kick off Wednesday in Mozambique, with doctors planning to inoculate 2,000 children over an 18-month period with an experimental vaccine against malaria called RTSS, a product developed by GlaxoSmithKline. A number of vaccines have been shown to increase the body’s defensive responses against malaria, but no product has been able to stop the spread of malaria among people living in areas at risk for the disease. However, researchers are confident that they are nearing a breakthrough in the fight against the disease, which kills 1 million Africans annually, most of them under the age of five years; RTSS provided a short-term immune response in the majority of participants in a small study in Gambia. Naturally, doctors would like to eradicate the disease, but experts say that even a partial benefit to children would be a success, as decreasing the number of children infected with malaria could significantly alter transmission rates.

Return to Vaccination News Home Page __» Right-click to "open in new window"

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.